Today’s issue of WorkCompRecap features a clinical update from Optum in the wake of the recent agreement between the FDA and Endo Pharmaceuticals to have Opana ER removed from the U.S. market, which highlighted the ongoing need for awareness on the safety of opioid analgesics.
While Opana ER’s benefits apparently no longer outweighed its risks, Optum noted that the question of whether opioid analgesics should continue to be used remains, and in their view, they still have a role in the treatment of injury-related pain, primarily though in acute circumstances like fractures or crush injuries, and post surgery to control pain that may not be controlled with other drugs. It is also critical that plans for ongoing pain management, phasing out opioids, and a date for discontinuation of opioids are established. Optum also covers points regarding making sure that patients demonstrate understanding of the benefits and risks involved, and discusses the evaluation of whether or not opioid use, while not typically recommended in chronic injury-related pain, may have valid cases where prudent usage makes sense.
Read the full update by clicking here!